Sign in
Enrolling by invitationPhase 1

Continued Treatment and Safety Monitoring for People With Certain Cancers

Follows people with blood cancers and solid tumors who continue study drugs long term.

Key facts

Who runs it
Janssen Research & Development, LLC
Where
Seoul, South KoreaSee the siteAlso in 14 other countries, 41 sites
Registry title
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Status
Enrolling by invitation
Phase
Phase 1
People taking part
120 people, planned
Started
30 Dec 2024
Expected to end
29 Dec 2028
Type of study
Interventional
Treatments tested
  • JNJ-75348780
  • JNJ-67856633
  • JNJ-54179060
  • JNJ-64264681
  • JNJ-74856665
  • JNJ-70218902
  • JNJ-64619178
  • JNJ-80948543
  • JNJ-87801493
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who already took part in a linked parent study and received study treatment there. They continue treatment and safety checks here.

Age
18 years and older
Sex
All sexes can join
Disease stage
The record lists blood cancers (acute myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, myelodysplastic syndromes), advanced solid tumors and metastatic castration-resistant prostate cancer. Stage details depend on the linked parent study.
Earlier treatment
Must have taken part in a parent study linked to this platform study and received study treatment there first.

Main reasons for not taking part

  • Any condition that puts the person at significant risk or gets in the way of the study, in the investigator's opinion
  • Unacceptable side effects or clear disease progression at the time of rollover
  • Meeting any exclusion criteria of the linked parent study appendix

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Have participated in a parent study, with a linked intervention specific appendix (ISA) within this platform study, in which they initially received study treatment(s) prior to rolling over to this platform study
  • Satisfy all ISA specific inclusion criteria
  • Sign an informed consent form (ICF) (or their legally acceptable representative must sign) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the platform study with details per the relevant ISA
  • Be willing and able to adhere to the lifestyle restrictions specified in the relevant ISA

Who cannot take part

  • Have any condition or situation which, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study
  • Have unacceptable toxicities or overt disease progression observed at time of rollover to the respective ISA
  • Meets any exclusion criteria within the pertinent ISA

Where in South Korea

Also in 14 other countries, 41 sites

  • Severance Hospital, Yonsei University Health SystemSeoul, South KoreaEnrolling by invitation

About the trial

What the trial wants to find out

The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the blood and bone marrow in which the bone marrow makes a large number of abnormal blood cells) and advanced solid tumors and metastatic castration-resistant prostate cancer (mCRPC).

The group in the trial

  • Long Term Safety Assessment (Platform Study)Other group

    The platform rollover study provides continued long-term access to study treatment(s) (JNJ-64264681; JNJ-67856633 (safimaltib); JNJ-54179060 (ibrutinib); JNJ-75348780; JNJ-74856665; JNJ-64619178; JNJ-70218902; JNJ-80948543; JNJ-87801493) for participants currently receiving the active study treatment in parent studies and deriving benefit from it. Eligible participants in parent study will rollover to this platform study which will be adapted into Intervention Specific Appendix (ISA) within the platform study. Participants will initiate the platform study under the relevant ISA, and will continue to receive study treatment at the dose they received in parent study.

    Treatment: JNJ-75348780, JNJ-67856633, JNJ-54179060, JNJ-64264681, JNJ-74856665, JNJ-70218902, JNJ-64619178, JNJ-80948543, and JNJ-87801493

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring
Plain-language title
Continued Treatment and Safety Monitoring for People With Certain CancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026